Featured Research

from universities, journals, and other organizations

The Protein IRF4 Takes Control Of Inflammation In The Gut

Date:
June 5, 2008
Source:
Journal of Clinical Investigation
Summary:
Individuals with inflammatory bowel diseases (IBDs) experience episodes of inflammation in their gut that can cause abdominal pain, vomiting, and diarrhea, among other things. Exactly what causes IBD has not been determined but it is now considered to involve inappropriate over activation of the immune system in the gut, and the proinflammatory factor IL-6 is thought to have a crucial role in this.

Individuals with inflammatory bowel diseases (IBDs) experience episodes of inflammation in their gut that can cause abdominal pain, vomiting, and diarrhea, among other things.

Exactly what causes IBD has not been determined but it is now considered to involve inappropriate over activation of the immune system in the gut, and the proinflammatory factor IL-6 is thought to have a crucial role in this.

New insight into the molecular mechanisms controlling IL-6 production in a mouse model of IBDs has now been provided by Markus Neurath and colleagues, at the University of Mainz, Germany, and might lead to the development of new drugs to treat individuals with IBDs.

Initial analysis indicated that a molecule known as IRF4, which regulates several functions in immune cells known as T cells, was expressed at higher levels in T cells in the gut of individuals with IBDs than in the gut of healthy individuals.

Consistent with increased IRF4 having an important role in the development of IBD, T cells from mice lacking IRF4 did not cause intestinal inflammation when transplanted into immunodeficient mice, whereas normal T cells did. Further, IRF4-deficient mice were protected from intestinal inflammation in two other models of IBD, and this protection was overcome by the administration of IL-6 to the mice.

The authors therefore conclude that IRF4 is a crucial regulator of IL-6 production in the intestine and that targeting IRF4 might provide a new approach to treating individuals with IBDs.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell--derived IL-6. Journal of Clinical Investigation, June 5, 2008

Cite This Page:

Journal of Clinical Investigation. "The Protein IRF4 Takes Control Of Inflammation In The Gut." ScienceDaily. ScienceDaily, 5 June 2008. <www.sciencedaily.com/releases/2008/06/080605203340.htm>.
Journal of Clinical Investigation. (2008, June 5). The Protein IRF4 Takes Control Of Inflammation In The Gut. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2008/06/080605203340.htm
Journal of Clinical Investigation. "The Protein IRF4 Takes Control Of Inflammation In The Gut." ScienceDaily. www.sciencedaily.com/releases/2008/06/080605203340.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins